SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

Correspondence 0001493152-24-030778 from IMPACT BIOMEDICAL INC. (IBO)

IMPACT BIOMEDICAL INC.
Date: Aug. 8, 2024 · CIK: 0001834105 · Accession: 0001493152-24-030778

AI Filing Summary & Sentiment

File numbers found in text: 333-275062

Date
Aug. 8, 2024
Author
REVERE SECURITIES, LLC
Form
CORRESP
Company
IMPACT BIOMEDICAL INC.

Letter

REVERE SECURITIES, LLC

Lexington Avenue, 16th Floor

New York, New York 10022

August 8, 2024

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

F Street, N.E.

Washington, DC 20549

Attention: Daniel Crawford

Re: Impact BioMedical Inc.

Registration Statement on Form S-1, as amended

File No. 333-275062

REQUEST FOR ACCELERATION OF EFFECTIVENESS

Requested Date: Monday, August 12, 2024

Requested Time: 4:00 p.m., Eastern Time

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), we, as representative of the underwriters of the proposed initial public offering of Impact BioMedical Inc. (the “Company”), hereby join the Company’s request that the effective date of the above-referenced registration statement be accelerated so that it will be declared effective at 4:00 p.m., Eastern Time, on Monday August 12, 2024, or as soon thereafter as possible.

Pursuant to Rule 460 under the Securities Act, we hereby advise that we will distribute as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus.

The undersigned advises that it has complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

Very truly yours,
REVERE SECURITIES, LLC

Show Raw Text
CORRESP
1
filename1.htm

REVERE
SECURITIES, LLC

560
Lexington Avenue, 16th Floor

New
York, New York 10022

August
8, 2024

VIA
EDGAR

United
States Securities and Exchange Commission

Division of Corporation Finance

Office
of Life Sciences

100
F Street, N.E.

Washington, DC 20549

Attention:
Daniel Crawford

Re:
Impact BioMedical Inc.

Registration
Statement on Form S-1, as amended

File
No. 333-275062

REQUEST
FOR ACCELERATION OF EFFECTIVENESS

Requested
Date: Monday, August 12, 2024

Requested
Time: 4:00 p.m., Eastern Time

Ladies
and Gentlemen:

Pursuant
to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), we, as representative of the underwriters
of the proposed initial public offering of Impact BioMedical Inc. (the “Company”), hereby join the Company’s request
that the effective date of the above-referenced registration statement be accelerated so that it will be declared effective at 4:00 p.m.,
Eastern Time, on Monday August 12, 2024, or as soon thereafter as possible.

Pursuant
to Rule 460 under the Securities Act, we hereby advise that we will distribute as many copies of the proposed form of preliminary prospectus
as appears to be reasonable to secure adequate distribution of the preliminary prospectus.

The
undersigned advises that it has complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange
Act of 1934, as amended.

    Very truly yours,

    REVERE SECURITIES, LLC

    By:
    /s/ Bill
    Moreno

    Name:
    Bill Moreno

    Title:
    Chairman & CEO